Arrow Mark Colorado Holdings LLC Chimerix Inc Transaction History

Arrow Mark Colorado Holdings LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.3 - $2.72 $276,441 - $578,399	-212,647 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $7.59 Million - $16.6 Million	-3,933,314 Reduced 94.87%	212,647 $500,000
Q2 2019 Aug 14, 2019	SELL	$2.05 - $4.32 $2.93 Million - $6.17 Million	-1,429,096 Reduced 25.63%	4,145,961 $17.9 Million
Q1 2019 May 15, 2019	BUY	$1.79 - $3.12 $1.53 Million - $2.67 Million	857,104 Added 18.17%	5,575,057 $11.7 Million
Q4 2018 Feb 14, 2019	BUY	$2.24 - $3.9 $1.62 Million - $2.82 Million	722,753 Added 18.09%	4,717,953 $12.1 Million
Q3 2018 Nov 14, 2018	BUY	$3.58 - $4.9 $344,621 - $471,688	96,263 Added 2.47%	3,995,200 $15.5 Million
Q2 2018 Aug 14, 2018	BUY	$4.43 - $5.14 $3.34 Million - $3.88 Million	754,716 Added 24.0%	3,898,937 $18.6 Million
Q1 2018 May 15, 2018	BUY	$4.65 - $5.9 $2.03 Million - $2.57 Million	436,235 Added 16.11%	3,144,221 $16.4 Million
Q4 2017 Feb 14, 2018	BUY	$4.32 - $5.52 $4.31 Million - $5.5 Million	996,936 Added 58.26%	2,707,986 $12.5 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.25 $7.44 Million - $8.98 Million	1,711,050	1,711,050 $8.98 Million

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.